Oncology Data Services
Breast Cancer Program Statistics
The breast cancer screening program at Harris Breast Center, within the Boone Hospital Center for Advanced Medicine is a state-of-the-art facility for screening and diagnosis of breast cancer. Exams that are offered include 3D mammography, breast ultrasound and breast MRI along with US, stereotactic and MRI guided biopsy. Three Breast Imaging Specialists from Radiology Consultants, Inc. staff the clinic. Dr. Terry Elwing, MD; Dr. Logan Frank, MD; and Dr. Barbara Tellerman, MD. They have over 50 years of combined experience interpreting mammography and performing breast imaging guided procedures. Each quarter, they assess their program for quality and accuracy compared to national standards and are proud to offer you care at a level that surpasses the national benchmarks for quality. These results are based on the following criteria.
Review of Non-Small Cell Lung Cancer Cases to Determine Reason for No Treatment
The Cancer Committee commissioned a review of 176 cases of non-small cell lung carcinoma diagnosed from 2009-2015 who did not appear to have treatment initiated. The purpose was to delve more deeply into these cases to determine (1) whether these observations were accurate, and if so (2) the reasons for no treatment.
Study of Referral for Potential Neoadjuvant Therapy for Her-2 Positive Breast Cancer
Breast Axillary Ultrasound Study Findings
In April 2014, BHC completed a Quality Improvement project regarding breast axillary ultrasound study findings.
To improve preoperative diagnosis of lymph node mets, we should consider doing axillary US on any outside case that has not been adequately imaged in addition to stereotactic biopsy cases in which invasive cancer is diagnosed. Education of the breast imaging specialists and technologists involved in breast imaging will also be performed to aide in improving our diagnostic capabilities.
Stage III NSCLC Lung Study for the Assessment of Evaluation and Treatment Planning Conclusion
We examined the outcome of 114 patients with Stage III non-small cell lung cancer from the BHC Cancer Registry. The choice of consolidation chemotherapy was up to the physician and patient. In general, those patients who received consolidation chemotherapy had a good enough performance status that allowed for this treatment. The results were interesting, showing a 20% improvement in overall 1 year survival, but the 5-year survival was the nearly the same, showing an insignificant difference of 21 vs 25.6% overall survival.